May 26, 2021
AIM ImmunoTech Announces Positive Safety Data from the Third Cohort of Its Phase 1 Intranasal Clinical Trial
May 18, 2021
AIM ImmunoTech Provides First Quarter 2021 Business Update
May 03, 2021
AIM ImmunoTech CEO Thomas K. Equels Participates in Fireside Chat with Ascendiant Capital Markets Analyst Ed Woo
Apr 27, 2021
AIM ImmunoTech Announces Positive Safety Data in Second Cohort of Phase 1 Clinical Study Investigating Intranasal Administration of Ampligen as a Potential Prophylaxis or Treatment for COVID-19 and Other Respiratory Viral Diseases
Apr 07, 2021
AIM ImmunoTech Announces Positive Safety Data in First Cohort of Phase 1 Clinical Study Investigating Intranasal Administration of Ampligen as a Potential Prophylaxis or Treatment for COVID-19 and Other Respiratory Viral Diseases
Mar 31, 2021
AIM ImmunoTech Reports 2020 Year-End Financial Results
Mar 22, 2021
AIM ImmunoTech Announces Addition of Single-Agent Ampligen Arm to Cancer Center's Ongoing Study in Cancer Patients with COVID-19
Mar 11, 2021
AIM ImmunoTech to Present at the Q1 Virtual Investor Summit on March 24th
Mar 10, 2021
AIM ImmunoTech to Participate at M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference
Mar 08, 2021
AIM ImmunoTech Announces First Healthy Subjects Dosed in Phase 1 Intranasal Ampligen Clinical Study
 9   10   11   12   13     14    15   16   17   18   19 
 <<   <   >   >>